FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20049

OMB APP	ROVAL
OMP Number	2225.02

 $\begin{array}{ll} \text{OMB Number:} & 3235\text{-}0287 \\ \text{Estimated average burden} \\ \text{hours per response:} & 0.5 \\ \end{array}$ 

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# Filed purcuant to Section 16(a) of the Securities Evolution Act of 1024

moduc	don I(b).			ı ilcu							pany Act			) <del>-1</del>					
Name and Address of Reporting Person*  Murray Lilian Shackelford					2. Issuer Name <b>and</b> Ticker or Trading Symbol Arcadia Biosciences, Inc. [ RKDA ]								(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>iviuiiu</u> y	Lillian O	<u>liuckerroru</u>													X Directo			10% Ov	
(Last) (First) (Middle) C/O ARCADIA BIOSCIENCES, INC. 202 COUSTEAU PLACE, SUITE 105				3. Date of Earliest Transaction (Month/Day/Year) 06/06/2018											Officer (give title below)		Other (s below)		
				4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)						
Street) DAVIS	C	A :	95618											- 1	X Form f	iled by Moi		orting Perso	
(City)	(S	tate)	(Zip)																
		Tab	le I - Noi	n-Deriva	tive S	Securit	es A	cquire	ed, D	isp	osed c	of, o	r Ben	eficial	ly Owned				
Title of Security (Instr. 3)  2. Transa Date (Month/D.				Execution Date,			e, Transaction Dispose Code (Instr. 5)			urities Acquired (A) sed Of (D) (Instr. 3, 4			Securitie Benefici Owned F	5. Amount of Securities Beneficially Owned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								ode \	,	Amount		(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
		Т	able II -	Derivati (e.g., ρι											Owned				
Title of Derivative Gecurity Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any				(A) S. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amount of Securities Underlying Derivative Se (Instr. 3 and 4)						8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
														Amount					

Date Exercisable

(1)

Expiration Date

06/06/2028

Title

Common

Stock

## Explanation of Responses:

\$10.8

1. The option vests in three equal installments occurring on the first, second and third anniversary of the date of grant.

### Remarks:

Common Stock (right to buy)

<u>Lilian Shackelford Murray, by</u>
<u>Attorney-in-Fact, Pamela</u>
<u>06/08/2018</u>
<u>Haley</u>

of Shares

6,408

\$0.00

6,408

D

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/06/2018

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

(A)

6,408

(D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.